ISSN: 1544-1873

Journal Home

Journal Guideline

Current Osteoporosis Reports Q1 Unclaimed

Current Science, Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Osteoporosis Reports is a journal indexed in SJR in Endocrinology, Diabetes and Metabolism with an H index of 84. It has a price of 3190 €. It has an SJR impact factor of 1,477 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,477.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Endocrinology, Diabetes and Metabolism (Q1)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,477

SJR Impact factor

84

H Index

58

Total Docs (Last Year)

192

Total Docs (3 years)

5774

Total Refs

1023

Total Cites (3 years)

192

Citable Docs (3 years)

5.48

Cites/Doc (2 years)

99.55

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Endocrine Reviews Q1
Nature Reviews Endocrinology Q1
Nature Metabolism Q1
Diabetes Care Q1
Bone Research Q1

Compare this journals

Aims and Scope

Best articles by citations

The Impact of Exercise in Rodent Models of Chronic Pain

Cellular Processes by Which Osteoblasts and Osteocytes Control Bone Mineral Deposition and Maturation Revealed by Stage-Specific EphrinB2 Knockdown

Etidronate: What is its place in treatment of primary osteoporosis and other demineralizing diseases today?

The Role of the Immune Cells in Fracture Healing

Osteomalacia

New thoughts about estrogen therapy from the Women's Health Initiative

Rodent Models of Aging Bone: An Update

Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment

Use of highly potent bisphosphonates in the treatment of osteoporosis

Correction to: Stopping Denosumab

Epidemiology of fracture risk in the Women's Health Initiative

Prescreening tools to determine who needs DXA

SHOW MORE ARTICLES

Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?

Renal Osteodystrophy or Kidney-Induced Osteoporosis?

Quality Improvement Initiatives in Fragility Fracture Care and Prevention

Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw

Orthobiologics in the Augmentation of Osteoporotic Fractures

Evaluation and correction of low vitamin D status

Muscle-Bone Crosstalk in Amyotrophic Lateral Sclerosis

Mechanism of action of bisphosphonates

Investigating Osteocytic Perilacunar/Canalicular Remodeling

Diabetes Medications and Bone

Mechanisms and Mediators That Drive Arthritis Pain

Androgen Deprivation and Bone